Join the Harold C. Simmons Comprehensive Cancer Center on September 20-21, 2019, for the Wendy & Emery Reves International Breast Cancer Symposium.
The Reves Symposium is a premier event at UT Southwestern whose objectives are to review the recent progress in breast cancer research and improvements in the clinical care of patients with breast cancer. The Reves Symposium provides information on the latest laboratory-based translational discoveries and new technologies, while exploring developments in treatment options, clinical trials, and population sciences.
Reves Symposium attendees include breast cancer providers and nursing professionals, basic and translational scientists, physician-scientists, clinical trialists, laboratory-based postdoctoral and clinical fellows, graduate students, patient advocates, and interested individuals from industry and North Texas communities.
Carlos L. Arteaga, M.D.
UT Southwestern Simmons Comprehensive Cancer Center
Carlos Caldas, M.D.
University of Cambridge
Lisa Carey, M.D.
University of North Carolina at Chapel Hill
SESSION 1 Tumor Heterogeneity
8:30 – 9:00 a.m.
Nicholas Navin, Ph.D. MD Anderson Cancer Center
Breast cancer evolution: insights from single cell genomics
9:00 – 9:30 a.m.
Kornelia Polyak, M.D., Ph.D. Dana-Farber Cancer Institute/Harvard
Regulators of breast tumor heterogeneity
9:30 – 10:00 a.m.
Charles Swanton, M.D., Ph.D. The Francis Crick Institute, UK
Chromosomal instability and genome plasticity in cancer evolution, immune evasion and metastasis
10:20 – 11:00 a.m.
Lisa Carey, M.D. The University of North Carolina at Chapel Hill
SESSION 2 Cancer Risk and Health Disparities
11:00 – 11:30 a.m.
Timothy R. Rebbeck, Ph.D. Dana-Farber Cancer Institute/Harvard
Prediction and prevention of cancer in BRCA1/2 mutation carriers in the precision medicine era
11:30 – Noon
Olufunmilayo (Funmi) Olopade, M.D. University of Chicago Cancer Center
Genomic landscape of breast cancer in diverse populations
SESSION 3 Cell Cycle and CDK4/6 inhibitors
1:15 – 1:45 p.m.
Andrew Koff, Ph.D. Memorial Sloan Kettering Cancer Center
Senescence after growth arrest: a mechanism by which CDK4/6 inhibitors can exert their anti-tumor effects
1:45 – 2:15 p.m.
Nicholas C. Turner, M.D., Ph.D. Royal Marsden Hospital, UK
Determinants of response and resistance to CDK4/6 inhibitors in breast cancer
2:15 – 2:45 p.m.
Hope S. Rugo, M.D. University of California, San Francisco
SESSION 4 De-escalation of Therapy
3:00 – 3:30 p.m.
Armando Giuliano, M.D. Cedars-Sinai Hospital
ACOSOG Z0011: de-escalation of surgical management
3:30 – 4:00 p.m.
Joseph A. Sparano, M.D. Montefiore Medical Center
4:00 – 4:30 p.m.
Sara M. Tolaney, M.D., M.P.H. Dana-Farber Cancer Institute
SESSION 5 Breast Cancer Detection/Imaging
8:00 – 8:30 a.m.
Debra L. Monticciolo, M.D. Baylor Scott & White Medical Center
The science of screening and overdiagnosis
8:30 – 9:00 a.m.
Robert M. Nishikawa, Ph.D. University of Pittsburgh
Who is the better learner: radiologists or artificial intelligence?
9:05 – 9:45 a.m.
Carlos Caldas, M.D. University of Cambridge, UK
The new molecular taxonomy of breast cancer
SESSION 6 Steroid Nuclear Receptors
10:05 – 10:35 a.m.
Nikhil Wagle, M.D. Dana-Farber Cancer Institute/Harvard
Resistance to endocrine therapies and CDK4/6 inhibitors in ER+ metastatic breast cancer
10:35 – 11:05 a.m.
W. Lee Kraus, Ph.D. UTSW Simmons Cancer Center
Nuclear receptors. transcriptional enhancers, and gene regulation in breast cancers
11:15 – 11:45 a.m.
Rinath Jeselsohn, M.D. Dana-Farber Cancer Institute/Harvard
The activating in ER mutations in endocrine resistance
11:45 a.m. – 12:15 p.m.
Suzanne Conzen, M.D.
Friday, September 20 at 8:30am to 12:00am
Medical Education & Conference Center and Commons Food Court (NG)
6001 Forest Park Road, DALLAS, TX 75390
Login to interact with events, personalize your calendar, and get recommendations.